Merck recalls all supply of combo cholesterol drug

This is a summary. To read the whole story subscribe to

Merck & Co. said Tuesday that it’s recalling a combination cholesterol drug, wiping out the entire US stock, due to packaging defects that could reduce effectiveness.

Merck said the recall covers all four dose strengths and every batch distributed since Liptruzet was launched in May.

Both active ingredients in the drug remain available separately, though.

Merck, the world’s third-biggest drug maker, said some of the foil pouches holding the pills may allow air and moisture inside. There’s a remote chance that could decrease the drug’s effectiveness or change its properties. There are no reports of patients being harmed.

Liptruzet combines two popular drugs that work in complementary ways to reduce levels of LDL, or bad cholesterol, a common strategy for preventing heart attacks and strokes.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.